default author photo

Gongyan Chen

Harbin Medical University - Department of Medical Oncology

China

SCHOLARLY PAPERS

2

DOWNLOADS

291

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Furmonertinib (AST2818) Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multi-Center, Double-Blind, Randomized Phase 3 Study (FURLONG)

Number of pages: 53 Posted: 10 Jan 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Harbin Medical University - Department of Medical Oncology, Xuzhou Central Hospital - Department of Medical Oncology, China Medical University - Department of Medical Oncology, Zhengzhou University - Henan Provincial People's Hospital, The People's Hospital of Guangxi Zhuang Autonomous Region - Department of Medical Oncology, Xinjiang Medical University - Department of Pulmonary Medicine, Xuzhou Medical College - Department of Respiratory Medicine, Nantong Tumor Hospital - Department of Medical Oncology, Wenzhou Medical University - Department of Pulmonary and Critical Care Medicine, Dalian University - Department of Oncology, University of Science and Technology of China (USTC) - Department of Respiratory Medicine, Jilin Cancer Hospital - Department of Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Capital Medical University - Department of Oncology, Hebei University - Department of Medical Oncology, Jilin University (JLU) - Cancer Center, Nantong University - Department of Respiratory Medicine, Shanghai Allist Pharmaceutical Technology, Shanghai Allist Pharmaceutical Technology and Shanghai Allist Pharmaceutical Technology
Downloads 236 (323,233)

Abstract:

Loading...

Furmonertinib, AST2818, NSCLC, EGFR, TKI

2.

Central Nervous System Efficacy of Rezivertinib (BPI-7711) in Advanced NCLC Patients with EGFR T790m Mutation: A Pooled Analysis of Two Clinical Trials

Number of pages: 33 Posted: 20 Mar 2023
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Shanxi Medical University - First Hospital, Shanxi Medical University - Department of Medical Oncology, Zhengzhou University - Department of Respiratory Medicine, Harbin Medical University - Department of Medical Oncology, Army Medical University - Institute of Cancer, Zhengzhou University - Department of Oncology, Sichuan University - Department of Respiratory and Critical Care Medicine, Linyi Cancer Hospital - Department of Medical Oncology, Qingdao University - Affiliated Hospital, Sichuan Cancer Hospital - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Peking University - Department of Thoracic Medical Oncology, Qingdao University - Yantai Yuhuangding Hospital, Zhejiang University - The First Affiliated Hospital, Zhengzhou University - Henan Provincial People's Hospital, Bengbu Medical College - First Affiliated Hospital, Sichuan University - Department of Thoracic Oncology, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Guangdong Medical University - Department of Oncology, Shandong First Medical University - Department of Oncology, Chongqing University Cancer Hospital - Department of Palliative Care, Chongqing University Cancer Hospital, Soochow University - Department of Pulmonary and Critical Care Medicine, Xingtai Medical College - Cancer Center, Nanjing Medical University - Department of Oncology, People's Hospital of Deyang City - Department of Oncology, Xinjiang Medical University - Department of Pulmonary Medicine, Liuzhou People's Hospital - Department of Oncology, Dalian University - Department of Oncology, Central South University - Department of Respiratory Medicine, Henan University of Science and Technology - Department of Medical Oncology, Nanjing Medical University - Department of Respiratory Medicine, Government of the People's Republic of China - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Huazhong University of Science and Technology - Tongji Medical College, Henan University - Department of Oncology, China Medical University - Liaoning Cancer Hospital & Institute, Huazhong University of Science and Technology - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Department of Thoracic Surgery, Xuzhou Medical University - Department of Radiotherapy, Handan Central Hospital - Department of Oncology, Wenzhou Medical University - Second Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Medical Oncology, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Hubei University of Arts and Science - Department of Oncology, Zhejiang University - Key Laboratory of Respiratory Disease of Zhejiang Province, Shantou University - Department of Medical Oncology, Anhui Medical University - Department of Oncology, Soochow University - Second Affiliated Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 55 (1,010,164)

Abstract:

Loading...

Rezivertinib, BPI-7711, EGFR T790M mutation, CNS, NSCLC